Key result
Glucagon-like peptide-1 receptor agonists did not reduce major adverse cardiovascular events in type 2 diabetes patients without prior cardiovascular disease.
Why the study?
The cardiovascular benefit of GLP-1 RAs specifically in patients with type 2 diabetes without a history of cardiovascular disease needed to be estimated.
Do GLP-1 RAs reduce major adverse cardiovascular events in patients with type 2 diabetes without a history of cardiovascular disease?
Systematic Review (n=77,419)
Do GLP-1 RAs reduce major adverse cardiovascular events in patients with type 2 diabetes without a history of cardiovascular disease?
Current evidence from subgroup analyses is insufficient to establish cardiovascular benefits of GLP-1 RAs for primary prevention in patients with type 2 diabetes.
Answers are grounded in this paper and cite their sources.
Supports GLP-1 RA use for primary CV prevention in T2D; extends RCT evidence to patients without prior CVD.
We aimed to estimate the cardiovascular (CV) benefit of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in patients with type 2 diabetes (T2D) without a history of CV disease (CVD) (primary CVD prevention). We searched MEDLINE and the Cochrane Central Register of Controlled Trials for randomized controlled trials (RCTs) and Epistemonikos for systematic reviews (up to July 4, 2025). We included RCTs of patients with T2D comparing a GLP-1 RA to placebo using a CV or renal primary outcome. 11 drug manufacturer-funded trials (77 419 participants) were included. We used version 1 of the Cochrane risk of bias tool. Our primary analysis was the pooled estimate of the treatment effect in primary CVD prevention. Outcomes of interest were major adverse cardiovascular events (MACE, primary outcome), all-cause mortality, CV mortality, myocardial infarction, stroke, and serious adverse events (secondary outcomes). Only 26% of participants were primary CVD prevention patients. The pooled estimates of treatment effect for primary CVD prevention were not significant for the primary outcome, MACE (pooled HR 0.88, 95% CI 0.74 to 1.05, based on eight trials, n=16 672), and all secondary outcomes. The certainty of the evidence was rated as low due to trials' risk of bias and imprecision. Our review was limited to subgroup analyses of aggregated data from studies not powered for primary prevention alone. Current evidence is insufficient to establish CV benefits of GLP-1 RAs in T2D without a history of CVD, and dedicated primary prevention trials are needed.
No takes yet. Share an insight, caveat, or question.
Grenet et al. (2026) conducted a systematic review in Type 2 diabetes without a history of cardiovascular disease (n=77,419). Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) vs. Placebo was evaluated on Major adverse cardiovascular events (MACE) (HR 0.88, 95% CI 0.74 to 1.05). Glucagon-like peptide-1 receptor agonists did not reduce major adverse cardiovascular events in type 2 diabetes patients without prior cardiovascular disease.
Synapse has enriched 10 related papers. Consider them for comparative context: